The most common reason I hear for skipping interval training is not that it is hard. It is that three sessions a week will not fit in the calendar. A trial out of the University of Hong Kong just tested whether that scheduling rule was doing any real work, and the answer looks like no.
Researchers at HKUMed randomized 315 adults with central obesity into three groups: one 75 minute interval training session a week, three shorter interval sessions adding up to the same 75 minutes, or a health education control group with no prescribed exercise. Enrollment ran from September 2021 to September 2024, and the intervention lasted four months. The point of the design is that both exercise arms did exactly the same total weekly minutes at the same intensity. The only variable was how those minutes were packaged.
At 16 weeks, both exercise groups had similar reductions in total body fat mass, body fat percentage, and waist circumference, and similar improvements in cardiorespiratory fitness, all measured against the control group. Once weekly did not lag behind thrice weekly on any of those. The paper was published August 2, 2026 in Nature Communications.
Public health guidance has treated exercise frequency as if it were part of the dose. Spread it out, three times a week, ideally more. What this trial suggests is that for these outcomes, in this population, the weekly total was carrying the result and the frequency was mostly a delivery detail. That reframes the biggest practical barrier most people face. If you have written interval training off because you cannot find three separate windows, this says the barrier may have been the schedule rather than the training.
I also like the funding profile here, which is not something I get to say often. The work was funded by Hong Kong's General Research Fund, the University Grants Committee, and an HKU seed fund, with no supplement or fitness industry money behind it. That matters when a finding is this convenient for busy people.
This is one trial, not yet independently replicated, and it ran for four months in Hong Kong Chinese adults with central obesity. It measured body composition and fitness markers, not long term cardiovascular outcomes or mortality, and nothing was tracked past the four month window. It is also an equivalence finding: once weekly was not worse than thrice weekly. That is a different claim from once weekly being better, and anyone already managing three sessions should not read this as permission to cut back.
If you have been treating three sessions a week as the entry fee and paying it by doing nothing, this gives you a legitimate way in. Put 75 minutes of interval work in one block, on the day you actually have, and know that a real trial found it moved body fat and waist circumference about as much as splitting it up. Start conservatively, because 75 minutes of intervals in one sitting is a real training load and the recovery cost lands in one day instead of three. If you already train several times a week and it works, keep it. The useful takeaway is not that less is more. It is that the weekly total is what you should be protecting, and the calendar can bend around it.
No, and this is the part worth being careful about. The trial found that once weekly was not worse than thrice weekly at the same total volume. That is an equivalence result, not evidence that fewer sessions are better. If three sessions a week already fit your life, there is nothing here telling you to drop two of them. The finding is aimed at the person who is currently doing zero because three never fit.
Total body fat mass, body fat percentage, waist circumference, and cardiorespiratory fitness, over a four month intervention with a 16 week assessment point. It did not measure long term cardiovascular events, mortality, or whether the results hold past four months. So it is a body composition and fitness finding, not a longevity finding, and nobody has followed these participants far enough to say what happens after the trial ended.
The participants were 315 Hong Kong Chinese adults with central obesity, enrolled between September 2021 and September 2024. Generalizability to other populations and body types has not been established yet, and this is a single trial from a single research group that has not been independently replicated. That is why I would treat it as a promising reason to restructure your week rather than a settled rule.
Get the Daily Signal in your inbox each morning, verified and no hype, before you even open your phone.